The present invention relates generally to medical methods and apparatus. More particularly, the present invention relates to methods and apparatus for endobronchial residual lung volume reduction by passive deflation of hyperinflated segments with functional lung volume expansion as a result.
Chronic obstructive pulmonary disease is a significant medical problem affecting 16 million people or about 6% of the U.S. population. Specific diseases in this group include chronic bronchitis, asthmatic bronchitis, and emphysema. While a number of therapeutic interventions are used and have been proposed, none is completely effective, and chronic obstructive pulmonary disease remains the fourth most common cause of death in the United States. Thus, improved and alternative treatments and therapies would be of significant benefit.
Of particular interest to the present invention, lung function in patients suffering from some forms of chronic obstructive pulmonary disease can be improved by reducing the effective lung volume, typically by resecting diseased portions of the lung. Resection of diseased portions of the lungs both promotes expansion of the non-diseased regions of the lung and decreases the portion of inhaled air that goes into the lungs but is unable to transfer oxygen to the blood. Lung volume reduction is conventionally performed in open chest or thoracoscopic procedures where the lung is resected, typically using stapling devices having integral cutting blades.
While effective in many cases, conventional lung volume reduction surgery is significantly traumatic to the patient, even when thoracoscopic procedures are employed. Such procedures often result in the unintentional removal of healthy lung tissue and frequently leave perforations or other discontinuities in the lung, which result in air leakage from the remaining lung. Even technically successful procedures can cause respiratory failure, pneumonia, and death. In addition, many older or compromised patients are not able to be candidates for these procedures.
As an improvement over open surgical and minimally invasive lung volume reduction procedures, endobronchial lung volume reduction procedures have been proposed. For example, U.S. Pat. Nos. 6,258,100 and 6,679,264 describe placement of one-way valve structures in the airways leading to diseased lung regions. It is expected that the valve structures will allow air to be expelled from the diseased region of the lung while blocking reinflation of the diseased region. Thus, over time, the volume of the diseased region will be reduced and the patient condition will improve.
While promising, the use of implantable, one-way valve structures is problematic in at least several respects. The valves must be implanted prior to assessing whether they are functioning properly. Thus, if the valve fails to either allow expiratory flow from or inhibit inspiratory flow into the diseased region, that failure will only be determined after the valve structure has been implanted, requiring surgical removal. Additionally, even if the valve structure functions properly, many patients have diseased lung segments with collateral flow from adjacent, healthy lung segments. In those patients, the lung volume reduction of the diseased region will be significantly impaired, even after successfully occluding inspiration through the main airway leading to the diseased region, since air will enter collaterally from the adjacent healthy lung region. When implanting one-way valve structures, the existence of such collateral flow will only be evident after the lung region fails to deflate over time, requiring further treatment.
For these reasons, it would be desirable to provide improved and alternative methods and apparatus for effecting residual lung volume reduction in hyperinflated and other diseased lung regions. The methods and apparatus will preferably allow for passive deflation of an isolated lung region without the need to implant a one-way valve structure in the lung. The methods and apparatus will preferably be compatible with known protocols for occluding diseased lung segments and regions after deflation, such as placement of plugs and occluding members within the airways leading to such diseased segments and regions. Additionally, such methods and devices should be compatible with protocols for identifying and treating patients having diseased lung segments and regions which suffer from collateral flow with adjacent healthy lung regions. At least some of these objectives will be met by the inventions described hereinbelow.
Methods for performing minimally invasive and endobronchial lung volume reduction are described in the following patents and publications: U.S. Pat. Nos. 5,972,026; 6,083,255; 6,258,100; 6,287,290; 6,398,775; 6,527,761; 6,585,639; 6,679,264; 6,709,401; 6,878,141; 6,997,918; 2001/0051899; and 2004/0016435.
The present invention provides methods and apparatus for passively reducing the residual volume (the volume of air remaining after maximal exhalation) of a hyperinflated or otherwise diseased lung compartment or segment. By “passively reducing,” it is meant that air can be removed from the diseased lung region without the use of a vacuum aspiration to draw the air from the region. Typically, such passive reduction will rely on a non-implanted one-way flow structure, which permits air to be exhaled or exhausted from the lung region while preventing or inhibiting the inspiration of air back into the lung region. Thus, the methods of the present invention will not require the permanent implantation of valves or other structures prior to actually achieving the desired residual lung volume reduction, as with the one-way implantable valve structures of the prior art.
The methods and apparatus of the present invention can be terminated and all apparatus removed should it appear for any reason that the desired residual lung volume reduction is not being achieved. Commonly, such failure can be the result of collateral flow into the diseased lung region from adjacent healthy lung region(s). In such cases, steps can be taken to limit or stop the collateral flow and allow resumption of the passive lung volume reduction protocols. In other cases, it might be desirable or necessary to employ open surgical, thoracoscopic, or other surgical procedures for lung resection.
Patients who successfully achieve residual volume reduction of hyperinflated or other diseased lung regions in accordance with the principles of the present invention will typically have those regions sealed permanently to prevent reinflation. Such sealing can be achieved by a variety of known techniques, including the application of radiofrequency or other energy for shrinking or sealing the walls of the airways feeding the lung region. Alternatively, synthetic or biological glues could be used for achieving sealing of the airway walls. Most commonly, however, expandable plugs will be implanted in the airways leading to the deflated lung region to achieve the sealing.
In a first aspect of the present invention, methods for reducing the residual volume of a hyperinflated lung compartment comprise sealingly engaging a distal end of a catheter in an airway feeding the lung compartment. Air is allowed to be expelled from the lung compartment through a passage in the catheter while the patient is exhaling, and air is blocked from re-entering the lung compartment through the catheter passage while the patient is inhaling. As the residual volume diminishes, the hyperinflated lung compartment reduces in size freeing up the previously occupied space in the thoracic cavity. Consequently, a greater fraction of the Total Lung Capacity (TLC), which is the volumetric space contained in the thoracic cavity that is occupied by lung tissue after a full inhalation, becomes available for the healthier lung compartments to expand, and the volume of the lung available for gas exchange commonly referred to in clinical practice as the lung's Functional Vital Capacity (FVC) or Vital Capacity (VC) increases, the result of which is effectively a functional lung volume expansion.
The hyperinflated lung compartment will usually be substantially free of collateral flow from adjacent lung compartments, and optionally the patient can be tested for the presence of such collateral flow, for example using techniques taught in copending, commonly assigned application Ser. No. 11/296,951, filed on Dec. 7, 2005; Ser. No. 11/550,660, filed on Oct. 18, 2006; and application Ser. No. 11/428,762, filed on Jul. 5, 2006, the full disclosures of which are incorporated herein by reference.
Alternatively, the methods of the present invention for reducing residual lung volume can be performed in patients having collateral flow channels leading into the hyperinflated or other diseased lung compartment. In such cases, the collateral flow channels may first be blocked, for example, by introducing glues, occlusive particles, hydrogels or other blocking substances, as taught for example in copending application Ser. No. 11/684,950, filed on Mar. 12, 2007, the full disclosure of which is incorporated herein by reference. In other cases, where the flow channels are relatively small, those channels will partially or fully collapse as the residual lung volume is reduced. In such cases, the patient may be treated as if the collateral flow channels did not exist. The effectiveness of reduction in hyperinflation, however, will depend on the collateral resistance between the hyperinflated compartment and the neighboring compartments, as illustrated in
In all of the above methods, it may be desirable to introduce an oxygen-rich gas into the lung compartment while or after the lung volume is reduced in order to induce or promote absorption atelectasis. Absorption atelectasis promotes absorption of the remaining or residual gas in the compartment into the blood to further reduce the volume, either before or after permanent sealing of the lung volume compartment or segment.
In a second aspect, the present invention provides catheters for isolating and deflating hyperinflated and other diseased lung compartments. The catheter comprises a catheter body, an expandable occluding member on the catheter body, and a one-way flow element associated with the catheter body. The catheter body usually has a distal end, a proximal end, and at least one lumen extending from a location at or near the distal end to a location at or near the proximal end. At least a distal portion of the catheter body is adapted to be advanced into and through the airways of a lung so that the distal end can reach an airway that feeds a target lung compartment or segment to be treated. The expandable occluding member is disposed near the distal end of the catheter body and is adapted to be expanded in the airway that feeds the target lung compartment or segment so that said compartment or segment can be isolated, with access provided only through the lumen or catheter body when the occluding member is expanded. The one-way flow element is adapted to be disposed within or in-line with the lumen of the catheter body in order to allow flow in a distal-to-proximal direction so that air will be expelled from the isolated lung compartment or segment as the patient exhales. The one-way flow element, however, inhibits or prevents flow through the lumen in a proximal-to-distal direction so that air cannot enter the isolated lung compartment or segment while the patient is inhaling.
For the intended endobronchial deployment, the catheter body will typically have a length in the range from 20 cm to 200 cm, preferably from 80 cm to 120 cm, and a diameter near the distal end in the range from 0.1 mm to 10 mm, preferably from 1 mm to 5 mm. The expandable occluding member will typically be an inflatable balloon or cuff, where the balloon or cuff has a width in the range from 1 mm to 30 mm, preferably from 5 mm to 20 mm, when inflated. The one-way flow element is typically a conventional one-way flow valve, such as a duck-bill valve, a flap valve, or the like, which is disposed in the lumen of the catheter body, either near the distal end or at any other point within the lumen. Alternatively, the one-way flow element could be provided as a separate component, for example provided in a hub which is detachably mounted at the proximal end of the catheter body. In other instances, it might be desirable to provide two or more one-way flow elements in series within the lumen or otherwise provided in-line with the lumen in order to enhance sealing in the inspiratory direction through the lumen.
In a third aspect of the present invention, a method for determining whether collateral ventilation of a hyperinflated lung compartment is present may involve: sealing a distal end of a catheter in an airway feeding the lung compartment; allowing air to be expelled from the lung compartment through a passage in the catheter while the patient is exhaling; blocking air from entering the lung compartment through the catheter passage while the patient is inhaling; comparing an image of the lung compartment with an earlier image of the lung compartment acquired before the sealing step; and determining whether collateral ventilation is present in the lung compartment, based on comparing the image and the earlier image. In one embodiment, the compared images are CT scans, although in other embodiments alternative imaging modalities may be used, such as MRI, conventional radiographs and/or the like. Typically, though not necessarily, the before and after images will be compared based on size, with a smaller size after catheter placement indicating a lack of significant collateral ventilation and little or no change in size indicating likely significant collateral ventilation.
Optionally, one embodiment may involve advancing the catheter through a bronchoscope to position the catheter distal end in the airway before sealing. In one such embodiment, the method may also involve: detaching a hub from a proximal end of the catheter; removing the bronchoscope from the airway by sliding it proximally over the catheter, thus leaving the catheter in the airway; and acquiring the image of the lung compartment. The catheter may be left in the airway for any suitable amount of time before acquiring the image—for example in one embodiment between about five minutes and about twenty-four hours. In some embodiments, where it is determined that there is minimal or no significant collateral ventilation of the lung compartment, the method may further include treating the airway to permanently limit airflow into the lung compartment.
These and other aspects and embodiments are described in further detail below, with reference to the attached drawing figures.
Referring to
The catheter 10 is equipped to seal the area between the catheter body 12 and the bronchial wall such that only the lumen 18 is communicating with the airways distal to the seal. The seal, or isolation, is accomplished by the use of the occluding member 15, such as an inflatable member, attached to (or near) the distal tip 14 of the catheter 10. When there is an absence of collateral channels connecting the targeted isolated compartment to the rest of the lung, the isolated compartment will unsuccessfully attempt to draw air from the catheter lumen 18 during inspiration of normal respiration of the patient. Hence, during exhalation no air is returned to the catheter lumen. In the presence of collateral channels, an additional amount of air is available to the isolated compartment during the inspiratory phase of each breath, namely the air traveling from the neighboring compartment(s) through the collateral channels, which enables volumetric expansion of the isolated compartment during inspiration, resulting during expiration in air movement away from the isolated compartment to atmosphere through the catheter lumen and the collateral channels. If it is desired to perform Endobronchial Volume Reduction (EVR) on a lung compartment, the lung compartment may be analyzed for collateral ventilation prior to treatment to determine the likelihood of success of such treatment. Further, if undesired levels of collateral ventilation are measured, the collateral ventilation may be reduced to a desired level prior to treatment to ensure success of such treatment.
The present invention relies on placement of a one-way flow element within or in-line with the lumen 18 so that flow from an isolated lung compartment or segment (as described hereinbelow) may occur in a distal-to-proximal direction but flow back into the lung compartment or segment is inhibited or blocked in the proximal-to-distal direction. As shown in
Alternatively or additionally, the one-way flow element 22 could be provided anywhere else in the lumen 18, and two, three, four, or more such valve structures could be included in order to provide redundancy. In some embodiments where the one-way flow element 22 (or elements) is located within the lumen 18 of the catheter body 12, the hub 20 may be removable, or alternatively the catheter 10 may not include a hub. As will be explained further below, this may facilitate leaving the catheter 10 in a patient for diagnostic and/or treatment purposes. For example, if the catheter 10 is advanced into a patient through a bronchoscope, the hub 20 may be detached to allow the bronchoscope to be removed proximally over the catheter 10, thus leaving the catheter body 12 with the one-way flow element 22 in the patient.
As a third option, a one-way valve structure 26 in the form of a flap valve could be provided within the hub 20. The hub 20 could be removable or permanently fixed to the catheter body 12. Other structures for providing in-line flow control could also be utilized.
In some embodiments, the catheter 10 may be coupled with a one-way valve, a flow-measuring device or/and a pressure sensor, all of which are external to the body of the patient and are placed in series so as to communicate with the catheter's inside lumen 18. The one-way valve prevents air from entering the target lung compartment from atmosphere but allows free air movement from the target lung compartment to atmosphere. The flow measuring device, the pressure sensor device and the one-way valve can be placed anywhere along the length of the catheter lumen 18. The seal provided by the catheter 10 results, during expiration, in air movement away from the isolated lung compartment to atmosphere through the catheter lumen 18 and the collateral channels. Thus, air is expelled through the catheter lumen 18 during each exhalation and will register as positive airflow on the flow-measuring device. Depending on the system dynamics, some air may be expelled through the catheter lumen 18 during exhalation in the absence of collateral channels, however at a different rate, volume and trend than that in the presence of collateral channels.
Use of the endobronchial lung volume reduction catheter 10 to reduce the residual volume of a diseased region DR of a lung L is illustrated beginning in
Referring now to
As shown in
As shown in
As described in greater detail in U.S. patent application Ser. No. 11/296,951, from which the present application claims priority and which has been previously incorporated by reference, a catheter 10 as described herein may also be used to determine whether collateral ventilation is present in a lung. The '951 application describes a number of methods and devices for use in determining such collateral ventilation. Additionally or alternatively to those methods/devices, in one embodiment a catheter 10 (as described above) may be advanced through a bronchoscope and deployed as described in relation to
In an alternative embodiment, the hub 20 of the catheter 10 may be left on, and the catheter 10 and bronchoscope may be left in the patient for a short time while an imaging study is performed.
While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
Minimally invasive methods, systems and devices are provided for qualitatively and quantitatively assessing collateral ventilation in the lungs.
On the opposite end of the catheter 10, external to the body of the patient, a one-way valve 16, a flow-measuring device 48 or/and a pressure sensor 40 are placed in series so as to communicate with the catheter's inside lumen. The one-way valve 16 prevents air from entering the target compartment Cs from atmosphere but allows free air movement from the target compartment Cs to atmosphere. When there is an absence of collateral channels connecting the targeted isolated compartment Cs to the rest of the lung, as illustrated in
This technique of measuring collateral flow in a lung compartment is analogous to adding another lung compartment, or lobe with infinitely large compliance, to the person's lungs, the added compartment being added externally. Depending on the system dynamics, some air may be expelled through the catheter lumen during exhalation in the absence of collateral channels, however at a different rate, volume and trend than that in the presence of collateral channels.
In other embodiments, the catheter 10 is connected with an accumulator or special container 42 as illustrated in
Optionally, a flow-measuring device 48 or/and a pressure sensor 40 may be included, as illustrated in
It can be appreciated that measuring flow can take a variety of forms, such as but not limited to measuring flow directly with the flow-measuring device 48, and/or indirectly by measuring pressure with the pressure sensor 40, and can be measured anywhere along the catheter shaft 12 with or without a one-way valve 16 in conjunction with the flow sensor 48 and with or without an external special container 42.
Furthermore, a constant bias flow rate can be introduced into the sealed compartment Cs with amplitude significantly lower than the flow rate expected to be measured due to collateral flow via the separate lumen in the catheter 10. For example, if collateral flow measured at the flow meter 48 is expected to be in the range of 1 ml/min, the bias flow rate can be, but not limited to one tenth (0.1) or one one-hundredth (0.01) of that amount of equal or opposite amplitude. The purpose of the bias flow is to continuously detect for interruptions in the detection circuit (i.e., the working channel of the bronchoscope and any other tubing between the flow meter and catheter) such as kinks or clogs, and also to increase response time in the circuit (due to e.g. inertia). Still, a quick flush of gas at a high flow rate (which is distinguished from the collateral ventilation measurement flow rate) can periodically be introduced to assure an unclogged line.
In addition to determining the presence of collateral ventilation of a target lung compartment, the degree of collateral ventilation may be quantified by methods of the present invention. In one embodiment, the degree of collateral ventilation is quantified based on the resistance through the collateral system Rcoll. Rcoll can be determined based on the following equation:
where Rcoll constitutes the resistance of the collateral channels, Rsaw characterizes the resistance of the small airways, and
For the sake of simplicity, and as a means to carry out a proof of principle,
A catheter 34 is advanceable through the passageway 88, as illustrated in
At any given time, the compartment 31 may only communicate to atmosphere either via the catheter's inside lumen 37 representing Rsaw and/or the collateral pathway 41 representing Rcoll. Accordingly, during inspiration, as illustrated in
The volume of air flowing during inspiration and expiration can be quantified by the areas under the flow curves 50, 52. The total volume of air V0 entering the target compartment 31 via collateral channels 41 during inspiration can be represented by the colored area under the collateral flow curve 50 of
The following rigorous mathematical derivation demonstrates the validity of these statements and the relation stated in Eq. 1:
Conservation of mass states that in the short-term steady state, the volume of air entering the target compartment 31 during inspiration must equal the volume of air leaving the same target compartment 31 during expiration, hence
V0=−(V3+V4) (2)
Furthermore, the mean rate of air entering and leaving the target compartment solely via collateral channels during a complete respiratory cycle (Tresp) can be determined as
where V2 over Tresp represents the net flow rate of air entering the target compartment 31 via the collateral channels 41 and returning to atmosphere through a different pathway during Tresp. Accordingly, V2 accounts for a fraction of V0, the total volume of air entering the target compartment 31 via collateral channels 41 during Tresp, hence V0 can be equally defined in terms of V1 and V2 as
V0=V1+V2 (4)
where V1 represents the amount of air entering the target compartment 31 via the collateral channels 41 and returning to atmosphere through the same pathway. Consequently, substitution of V0 from Eq. 4 into Eq. 3 yields
V1=−V3 (5)
and substitution of V0 from Eq. 2 into the left side of Eq. 4 following substitution of V1 from Eq. 5 into the right side of Eq. 4 results in
−V4=V2 (6)
Furthermore, the mean flow rate of air measured at the flowmeter 42 during Tresp can be represented as
where substitution of V4 from Eq. 6 into Eq. 7 yields
Ohms's law states that in the steady state
where
and substitution of Ps from Eq. 9 into Eq. 10 results in
after subsequently solving for
and division of Eq. 12 by
where the absolute value of Eq. 13 leads back to the aforementioned relation originally stated in Eq. 1.
The system illustrated in
Accordingly, the elasticity of the isolated compartment 31 is responsible for the volume of air obtainable solely across Rcoll during the inspiratory effort and subsequently delivered back to atmosphere through Rsaw and Rcoll during expiration. Pressure changes during respiration are induced by the variable pressure source, Pp1 representing the varying negative pleural pressure within the thoracic cavity during the respiratory cycle. An ideal diode 66 represents the one-way valve 16, which closes during inspiration and opens during expiration. Consequently, as shown in
Evaluation of Eqs. 1 & 8 by implementation of a computational model of the collateral system illustrated in
Similarly,
Therefore, the above described models and mathematical relationships can be used to provide a method which indicates the degree of collateral ventilation of the target lung compartment of a patient, such as generating an assessment of low, medium or high degree of collateral ventilation or a determination of collateral ventilation above or below a clinical threshold. In some embodiments, the method also quantifies the degree of collateral ventilation, such generating a value which represents Rcoll. Such a resistance value indicates the geometric size of the collateral channels in total for the lung compartment. Based on Poiseuille's Law with the assumption of laminar flow,
R∝(η×L)/r4 (14)
wherein η represents the viscosity of air, L represents the length of the collateral channels and r represents the radius of the collateral channels. The fourth power dependence upon radius allows an indication of the geometric space subject to collateral ventilation regardless of the length of the collateral channels.
The dynamic behavior of the system depicted in
At time t1=30 s, a known fixed amount of inert gas (qhe: 5-10 ml of 100% He) is rapidly injected into the target compartment Cs, while the rest of the lobe remains occluded; and the pressure (Ps) and the fraction of He (Fhe
As a result, the following methods may be performed for each compartment or segment independently: 1) Assess the degree of segmental hyperinflation, 2) Determine the state of segmental compliance, 3) Evaluate the extent of segmental collateral communications.
Segmental Hyperinflation
The degree of hyperinflation in the target segment, qs(0), can be determined by solving Eq. 16 for qs(0) and subsequently substituting qs(t1) from Eq. 20 into Eq. 16 after appropriate solution of Eq. 20 for qs(t1) as
Segmental Compliance
The state of compliance in the target segment, Cs, can be determined simply by solving Eq. 18 for Cs as
Segmental Collateral Resistance
A direct method for the quantitative determination of collateral system resistance in lungs, has been described above. Whereas, the calculation below offers an indirect way of determining segmental collateral resistance.
The compliance of the rest of the lobe, CL, can be determined by solving Eq. 19 for CL and subsequently substituting Cs with Eq. 23. Accordingly
As a result, the resistance to collateral flow/ventilation can alternatively be found by solving Eq. 15 for Rcoll and subsequent substitution into Eq. 15 of Cs from Eq. 24 and CL from Eq. 25 as
where Ceff is the effective compliance as defined in Eq. 15.
Additional Useful Calculation for Check and Balances of all Volumes
The degree of hyperinflation in the rest of the lobe, hence qL(0), can be determined by solving Eq. 17 for qL(0) and subsequently substituting qs(t2)+qL(t2) from Eq. 21 into Eq. 17 after appropriate solution of Eq. 21 for qs(t2)+qL(t2). Thus
Equation 26 provides an additional measurement for check and balances of all volumes at the end of the clinical procedure.
This application is a continuation of U.S. patent application Ser. No. 16/930,194, filed Jul. 15, 2020, now U.S. Pat. No. 11,413,045, which is a continuation of U.S. patent application Ser. No. 15/358,483, filed Nov. 22, 2016, now U.S. Pat. No. 10,758,239, which is a continuation of U.S. patent application Ser. No. 13/938,025, filed Jul. 9, 2013, now U.S. Pat. No. 9,533,116, which is a continuation of U.S. patent application Ser. No. 12/820,547, filed Jun. 22, 2010, now U.S. Pat. No. 8,496,006, which is a continuation-in-part of U.S. patent application Ser. No. 11/685,008, filed Mar. 12, 2007; U.S. patent application Ser. No. 12/820,547, is also a continuation-in-part of U.S. patent application Ser. No. 11/296,951, filed Dec. 7, 2005, now U.S. Pat. No. 7,883,471, which claims the benefit and priority of U.S. Provisional Patent Application No. 60/645,711, filed Jan. 20, 2005; 60/696,940, filed Jul. 5, 2005; and 60/699,289, filed Jul. 13, 2005. The full disclosures of all the above-referenced patent applications are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3322126 | Rusch et al. | May 1967 | A |
3498286 | Michael et al. | Mar 1970 | A |
3669098 | Takahashi | Jun 1972 | A |
3677262 | Zukowski | Jul 1972 | A |
3768504 | Rentsch | Oct 1973 | A |
3776222 | Smiddy | Dec 1973 | A |
3794026 | Jacobs | Feb 1974 | A |
3866599 | Johnson | Feb 1975 | A |
3913568 | Carpenter | Oct 1975 | A |
4041936 | Carden | Aug 1977 | A |
4134407 | Elam | Jan 1979 | A |
4147169 | Taylor | Apr 1979 | A |
4327720 | Bronson et al. | May 1982 | A |
4327721 | Goldin et al. | May 1982 | A |
4382442 | Jones | May 1983 | A |
4453545 | Inoue | Jun 1984 | A |
4468216 | Muto | Aug 1984 | A |
4470407 | Hussein | Sep 1984 | A |
4538607 | Saul | Sep 1985 | A |
4567882 | Heller | Feb 1986 | A |
4681093 | Ono et al. | Jul 1987 | A |
4716896 | Ackerman | Jan 1988 | A |
4742819 | George | May 1988 | A |
4762125 | Leiman et al. | Aug 1988 | A |
4784133 | Mackin | Nov 1988 | A |
4796639 | Snow et al. | Jan 1989 | A |
4819664 | Nazari | Apr 1989 | A |
4846153 | Berci | Jul 1989 | A |
4850371 | Broadhurst et al. | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4862874 | Kellner | Sep 1989 | A |
4896941 | Hayashi et al. | Jan 1990 | A |
4946440 | Hall | Aug 1990 | A |
4949716 | Chenoweth | Aug 1990 | A |
4955375 | Martinez | Sep 1990 | A |
4958932 | Kegelman et al. | Sep 1990 | A |
4961738 | Mackin | Oct 1990 | A |
4976710 | Mackin et al. | Dec 1990 | A |
5056529 | De Groot et al. | Oct 1991 | A |
5143062 | Peckham | Sep 1992 | A |
5146916 | Catalani | Sep 1992 | A |
5161525 | Kimm et al. | Nov 1992 | A |
5165420 | Strickland | Nov 1992 | A |
5181913 | Erlich | Jan 1993 | A |
5246012 | Strickland | Sep 1993 | A |
5285778 | Mackin | Feb 1994 | A |
5308325 | Quinn et al. | May 1994 | A |
5309903 | Long | May 1994 | A |
5329940 | Adair | Jul 1994 | A |
5331947 | Shturman et al. | Jul 1994 | A |
5361753 | Pothmann et al. | Nov 1994 | A |
5439444 | Andersen et al. | Aug 1995 | A |
5447165 | Gustafsson | Sep 1995 | A |
5477851 | Callaghan et al. | Dec 1995 | A |
5499625 | Frass et al. | Mar 1996 | A |
5546935 | Champeau | Aug 1996 | A |
5573005 | Ueda | Nov 1996 | A |
5588424 | Insler et al. | Dec 1996 | A |
5598840 | Iund et al. | Feb 1997 | A |
5624449 | Pham et al. | Apr 1997 | A |
5642730 | Baran | Jul 1997 | A |
5645519 | Lee et al. | Jul 1997 | A |
5653231 | Bell | Aug 1997 | A |
5660175 | Dayal | Aug 1997 | A |
5662712 | Pathak et al. | Sep 1997 | A |
5682880 | Brain | Nov 1997 | A |
5707352 | Sekins et al. | Jan 1998 | A |
5752921 | Orr | May 1998 | A |
5765557 | Warters | Jun 1998 | A |
5795322 | Boudewijn | Aug 1998 | A |
5800455 | Palermo et al. | Sep 1998 | A |
5893841 | Glickman | Apr 1999 | A |
5897528 | Schultz | Apr 1999 | A |
5915383 | Pagan | Jun 1999 | A |
5972026 | Laufer et al. | Oct 1999 | A |
5997546 | Foster et al. | Dec 1999 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6099546 | Gia | Aug 2000 | A |
6174307 | Daniel et al. | Jan 2001 | B1 |
6174323 | Biggs et al. | Jan 2001 | B1 |
RE37117 | Palermo | Mar 2001 | E |
6258100 | Alferness et al. | Jul 2001 | B1 |
6287290 | Perkins et al. | Sep 2001 | B1 |
6293951 | Alferness et al. | Sep 2001 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6398775 | Perkins et al. | Jun 2002 | B1 |
6527761 | Soltesz et al. | Mar 2003 | B1 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6609521 | Belani et al. | Aug 2003 | B1 |
6629951 | Laufer et al. | Oct 2003 | B2 |
6651672 | Roth et al. | Nov 2003 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6692494 | Cooper et al. | Feb 2004 | B1 |
6709401 | Perkins et al. | Mar 2004 | B2 |
6712812 | Roschak et al. | Mar 2004 | B2 |
6722360 | Doshi | Apr 2004 | B2 |
6749606 | Keast et al. | Jun 2004 | B2 |
6792947 | Bowden | Sep 2004 | B1 |
6878141 | Perkins et al. | Apr 2005 | B1 |
6886558 | Tanaka | May 2005 | B2 |
6941950 | Wilson et al. | Sep 2005 | B2 |
6997189 | Biggs et al. | Feb 2006 | B2 |
6997918 | Soltesz et al. | Feb 2006 | B2 |
7011094 | Rapacki et al. | Mar 2006 | B2 |
7022088 | Keast et al. | Apr 2006 | B2 |
7086398 | Tanaka | Aug 2006 | B2 |
7175644 | Cooper et al. | Feb 2007 | B2 |
7276077 | Zadno-Azizi et al. | Oct 2007 | B2 |
7449010 | Hayase et al. | Nov 2008 | B1 |
7588033 | Wondka | Sep 2009 | B2 |
7744594 | Yamazaki et al. | Jun 2010 | B2 |
7819840 | Burnside et al. | Oct 2010 | B2 |
7883471 | Aljuri et al. | Feb 2011 | B2 |
8137302 | Aljuri et al. | Mar 2012 | B2 |
8496006 | Aljuri | Jul 2013 | B2 |
8551043 | Crooms et al. | Oct 2013 | B2 |
9050094 | Aljuri et al. | Jun 2015 | B2 |
9533116 | Alijuri | Jan 2017 | B2 |
10314992 | Aljuri et al. | Jun 2019 | B2 |
10758239 | Aljuri | Sep 2020 | B2 |
11298489 | Aljuri et al. | Apr 2022 | B2 |
11413045 | Aljuri | Aug 2022 | B2 |
20010051899 | Kawashima et al. | Dec 2001 | A1 |
20020049370 | Laufer et al. | Apr 2002 | A1 |
20020062120 | Perkins et al. | May 2002 | A1 |
20020087153 | Roschak et al. | Jul 2002 | A1 |
20020104544 | Ogushi et al. | Aug 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020111620 | Cooper et al. | Aug 2002 | A1 |
20020169413 | Keren et al. | Nov 2002 | A1 |
20030051733 | Kotmel | Mar 2003 | A1 |
20030171332 | Abraham et al. | Sep 2003 | A1 |
20030228344 | Fields et al. | Dec 2003 | A1 |
20040016435 | Deem et al. | Jan 2004 | A1 |
20040073201 | Cooper et al. | Apr 2004 | A1 |
20040220556 | Cooper et al. | Nov 2004 | A1 |
20040243016 | Sanderson et al. | Dec 2004 | A1 |
20050005936 | Wondka | Jan 2005 | A1 |
20050016530 | McCutcheon et al. | Jan 2005 | A1 |
20050022809 | Wondka | Feb 2005 | A1 |
20050126572 | Gosweiler | Jun 2005 | A1 |
20050166924 | Thomas et al. | Aug 2005 | A1 |
20050187561 | Lee-Sepsick et al. | Aug 2005 | A1 |
20050288684 | Aronson et al. | Dec 2005 | A1 |
20060095002 | Soltesz et al. | May 2006 | A1 |
20060102186 | Adler | May 2006 | A1 |
20060122647 | Callaghan et al. | Jun 2006 | A1 |
20060129134 | Kerr | Jun 2006 | A1 |
20060264772 | Aljuri et al. | Nov 2006 | A1 |
20060283462 | Fields et al. | Dec 2006 | A1 |
20070005083 | Sabanathan et al. | Jan 2007 | A1 |
20070096048 | Clerc | May 2007 | A1 |
20070142742 | Aljuri et al. | Jun 2007 | A1 |
20070225747 | Perkins et al. | Sep 2007 | A1 |
20080051719 | Nair et al. | Feb 2008 | A1 |
20080228130 | Aljuri et al. | Sep 2008 | A1 |
20080228137 | Aljuri et al. | Sep 2008 | A1 |
20090241964 | Aljuri et al. | Oct 2009 | A1 |
20090260625 | Wondka | Oct 2009 | A1 |
20100031964 | Turek et al. | Feb 2010 | A1 |
20110011406 | Blom et al. | Jan 2011 | A1 |
20110152678 | Aljuri et al. | Jun 2011 | A1 |
20110203594 | Brain | Aug 2011 | A1 |
20110259339 | Isaza | Oct 2011 | A1 |
20130296696 | Aljuri et al. | Nov 2013 | A1 |
20150231353 | Aljuri et al. | Aug 2015 | A1 |
20170071606 | Aljuri et al. | Mar 2017 | A1 |
20200405318 | Aljuri et al. | Dec 2020 | A1 |
20220184332 | Aljuri et al. | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
0791340 | Aug 1997 | EP |
0815803 | Jan 1998 | EP |
0982044 | Mar 2000 | EP |
1078601 | Feb 2001 | EP |
1078601 | Oct 2006 | EP |
2003507127 | Feb 2003 | JP |
2004504867 | Feb 2004 | JP |
2004512893 | Apr 2004 | JP |
2006314816 | Nov 2006 | JP |
WO-9210971 | Jul 1992 | WO |
WO-9533506 | Dec 1995 | WO |
WO-9844854 | Oct 1998 | WO |
WO-9848706 | Nov 1998 | WO |
WO-9849191 | Nov 1998 | WO |
WO-9901076 | Jan 1999 | WO |
WO-9917827 | Apr 1999 | WO |
WO-9920332 | Apr 1999 | WO |
WO-9932040 | Jul 1999 | WO |
WO-9934741 | Jul 1999 | WO |
WO-9964109 | Dec 1999 | WO |
WO-0041612 | Jul 2000 | WO |
WO-0051510 | Sep 2000 | WO |
WO-0062699 | Oct 2000 | WO |
WO-0102042 | Jan 2001 | WO |
WO-0103642 | Jan 2001 | WO |
WO-0110314 | Feb 2001 | WO |
WO-0113839 | Mar 2001 | WO |
WO-0113908 | Mar 2001 | WO |
WO-03022124 | Mar 2003 | WO |
WO-03022221 | Mar 2003 | WO |
03022221 | Jul 2003 | WO |
WO-2006055692 | May 2006 | WO |
WO-2006078451 | Jul 2006 | WO |
WO-2006091597 | Aug 2006 | WO |
WO-2008112797 | Sep 2008 | WO |
Entry |
---|
Office action dated Apr. 12, 2021 for U.S. Appl. No. 16/428,544. |
U.S. Appl. No. 16/428,544 Notice of Allowance dated Dec. 16, 2021. |
U.S. Appl. No. 14/703,670 Office Action dated Oct. 11, 2018. |
U.S. Appl. No. 14/703,670 Notice of Allowance dated Jan. 24, 2019. |
U.S. Appl. No. 16/930,194 Notice of Allowance dated Apr. 4, 2022. |
Becker et al., Lung Volumes Before and After Lung Volume Reduction Surgery, Am J Respir Crit Care Med, 1998; 157:1593-1599. |
Criner et al., Effect of Lung Volume Reduction Surgery on Diaphragm Strength, Am J Respir Crit Care Med, 1998; 157:1578-1585. |
European search report and opinion dated Oct. 13, 2015 for EP Application No. 08732032.1. |
European search report and opinion dated Nov. 16, 2009 for EP Application No. 06717427.6. |
Final Office action dated Oct. 11, 2018 for U.S. Appl. No. 14/703,670. |
Harada et al., Re-expansion of Refractory Atelectasis Using a Bronchofiberscope with a Balloon Cuff, Chest, Dec. 1983; 84:725-728. |
International search report and written opinion dated Aug. 26, 2008 for PCT/US2008/056706. |
Kotloff et al., “Comparison of Short-term Functional Outcomes Following Unilateral and Bilateral Lung Volume Reduction Surgery,” Chest. Apr. 1998;113(4):890-5. |
Morrell et al., “Collateral ventilation and gas exchange during airway occlusion in the normal human lung,” Am Rev Respir Dis. Mar. 1993;147(3):535-539. |
Notice of allowance dated Jan. 27, 209 for U.S. Appl. No. 14/706,670. |
Notice of allowance dated Feb. 2, 2015 for U.S. Appl. No. 12/407,709. |
Notice of allowance dated Mar. 24, 2020 for U.S. Appl. No. 15/358,483. |
Notice of allowance dated Mar. 26, 2013 for U.S. Appl. No. 12/820,547. |
Notice of Allowance dated Aug. 26, 2016 for U.S. Appl. No. 13/938,025. |
Office action dated Apr. 10, 2015 for U.S. Appl. No. 13/938,025. |
Office action dated Apr. 11, 2012 for U.S. Appl. No. 12/407,709. |
Office action dated Apr. 15, 2010 for U.S. Appl. No. 11/685,008. |
Office action dated Jul. 8, 2014 for U.S. Appl. No. 12/407,709. |
Office action dated Aug. 1, 2012 for U.S. Appl. No. 12/820,547. |
Office action dated Oct. 2, 2019 for U.S. Appl. No. 15/358,483. |
Office action dated Nov. 1, 2013 for U.S. Appl. No. 12/407,709. |
Office action dated Nov. 24, 2009 for U.S. Appl. No. 11/685,008. |
Office action dated Dec. 17, 2012 for U.S. Appl. No. 12/407,709. |
Office action dated Dec. 18, 2015 for U.S. Appl. No. 13/938,025. |
Ojo et al., Lung Volume reduction surgery alters management of pulmonary nodules in patients with severe COPD. Chest. Dec. 1997; 112(6): 1494-1500. |
Sclafani, “Clearing the Airways,” AARC Times, Jan. 1999, pp. 69-72. |
Snell, et al. The potential for bronchoscopic lung volume reduction using bronchial prostheses. Chest. Sep. 2003; 124(3):1073-1080. |
U.S. Appl. No. 11/428,762, filed Jul. 5, 2006. |
U.S. Appl. No. 60/828,496, filed Oct. 26, 2006. |
U.S. Appl. No. 14/703,670 Office Action dated Jan. 31, 2018. |
Woolcock et al., Mechanical Factors Influencing Collateral Ventilation In Human, Dog, And Pig Lungs, J Appl Physiol. Jan. 1971; 30(1):99-115. |
Burger et al., “Gas Exchange in the Parabronchial Lung of Birds: Experiments in Unidirectionally Ventilated Ducks”, Respiration Physiology, vol. 36, No. 1, Jan. 1979, pp. 19-37. |
Number | Date | Country | |
---|---|---|---|
20230000497 A1 | Jan 2023 | US |
Number | Date | Country | |
---|---|---|---|
60699289 | Jul 2005 | US | |
60696940 | Jul 2005 | US | |
60645711 | Jan 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16930194 | Jul 2020 | US |
Child | 17867990 | US | |
Parent | 15358483 | Nov 2016 | US |
Child | 16930194 | US | |
Parent | 13938025 | Jul 2013 | US |
Child | 15358483 | US | |
Parent | 12820547 | Jun 2010 | US |
Child | 13938025 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11685008 | Mar 2007 | US |
Child | 12820547 | US | |
Parent | 11296951 | Dec 2005 | US |
Child | 11685008 | US |